BioSpace News Archive

MEI Pharma, Inc. confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced in their 13-D filing of earlier today, to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of the Company’s clinical assets.

According to The Insight Partners market research titled ‘Colorectal Cancer Market to 2027 – Global Analysis and Forecasts by Modality, and End User’.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced the presentation of results from its Phase 1a single-ascending dose study of XmAb®564 in healthy volunteers.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s 1Q2023 unaudited condensed interim consolidated Financial Statements.

Hinge Bio, Inc., a privately-held biotechnology company, announced that Juha Punnonen, M.D., Ph.D. has joined the company as Chief Development Officer.

The Insight Partners published latest research study on “Optical Coherence Tomography Angiography Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Handheld Type and Tabletop Type) and End User (Hospitals, Clinics, and Others)

The Insight Partners recently published a report on “Artificial Heart Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact and Global Analysis – by System and Geography”, the global artificial heart market size is projected to grow from USD 1.98 billion in 2021 to USD 4.99 billion by 2028; it is expected to grow at a CAGR of 15.5% from 2022 to 2028.

Acticor Biotech, a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, is discussing with the FDA and the EMA its development program for the acute ischemic stroke indication.

The Insight Partners published latest research study on “Hydrocephalus Shunts Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028 - COVID-19 Impact and Global Analysis By Age Group, Type, Product, and End User”

Fluent BioSciences, a life science tools company, delivering single-cell technology to laboratories across the United States and abroad, collaborates with Genspace by sponsoring a community science workshop in Brooklyn, NY.